Welcome
Support Centre
10 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease
ISRCTN ISRCTN71212234
ClinicalTrials.gov identifier
Public title Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease
Scientific title
Acronym N/A
Serial number at source H14
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Lymphoma (Hodgkin's)
Participants - inclusion criteria 1. Hodgkin's lymphoma stage IIB, III or IV
2. Staging to include adequate documentation of systemic symptoms, and Computed Tomography (CT) scan (except stage IV)
3. Local hisopathological review of diagnosis
4. No medical contraindications to treatment protocols
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/1989
Anticipated end date 01/10/1993
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Patients are randomised to one of two chemotherapy regimens:
1. MOPP Regimen: Multi-drug chemotherapy with mustine, vincristine (Oncovin), procarbazine and prednisolone (MOPP) repeated every 4 weeks for a minimum of four courses.
2. MOPP/EVAP Regimen: Multi-drug chemotherapy with MOPP alternating every 2 weeks with etoposide, vinblastine, adriamycin and prednisolone (EVAP) for a minimum of eight courses of chemotherapy (ie four courses each of MOPP and EVAP).
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Cancer Research UK
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Cancer Research UK (CRUK) (UK)
  Address PO Box 123
Lincoln's Inn Fields
  City/town London
  Zip/Postcode WC2A 3PX
  Country United Kingdom
  Tel +44 (0)20 7317 5186
  Fax +44 (0)20 7487 4302
  Email kate.law@cancer.org.uk
  Sponsor website: http://www.cancer.org.uk
Date applied 01/07/2001
Last edited 29/05/2008
Date ISRCTN assigned 01/07/2001
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central